Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Share-based Compensation (2022 - 2025)

Zentalis Pharmaceuticals has reported Share-based Compensation over the past 4 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $3.1 million for Q4 2025, down 90.05% from a year ago — trailing twelve months through Dec 2025 was $20.7 million (down 69.2% YoY), and the annual figure for FY2025 was $20.7 million, down 69.2%.
  • Share-based Compensation for Q4 2025 was $3.1 million at Zentalis Pharmaceuticals, down from $4.8 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ZNTL hit a ceiling of $31.4 million in Q4 2024 and a floor of $3.1 million in Q4 2025.
  • Median Share-based Compensation over the past 4 years was $11.5 million (2024), compared with a mean of $11.9 million.
  • Biggest five-year swings in Share-based Compensation: surged 125.96% in 2024 and later tumbled 90.05% in 2025.
  • Zentalis Pharmaceuticals' Share-based Compensation stood at $9.6 million in 2022, then surged by 44.4% to $13.9 million in 2023, then surged by 125.96% to $31.4 million in 2024, then tumbled by 90.05% to $3.1 million in 2025.
  • The last three reported values for Share-based Compensation were $3.1 million (Q4 2025), $4.8 million (Q3 2025), and $6.3 million (Q2 2025) per Business Quant data.